News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 09 - 03

Efung News | Trinomab’s Global First Anti-RSV Monoclonal Antibody Xinduotuo®, Offering One-Shot, 9-M

On September 3, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Code: 688806, hereinafter referred to as "Trinomab") reached another significant milestone!Following the approval of Xintituo® (Generic Name: Stedostat Monoclonal Antibody Injection), the world's first innovative next-generation "tetanus shot," the company's independently developed global first recombinant anti-respiratory syncytial virus (RSV) fully human monoclonal antibody — Xinduotuo® (Generic Name: Ritevimab Monoclonal Antibody Injection, formerly known as TNM001 Injection) — has of...

浏览次数：4

查看详情>>

发布时间: 2026 - 09 - 02

Efung Honor| The Power of Youth in Hard-Tech Arena! Effice Capital's CEO Zhu Pai Named to Qimingpia

Today, Qimingpian officially released its "2026 China U35 Outstanding Young Investors" list, and Mr. Zhu Pai, CEO of Effice Capital, has been honored on this prestigious roster.In 2026, the primary market is taking shape in a new landscape defined by "deep tech innovation, value consolidation, and industrial symbiosis." AI, humanoid robotics, semiconductors, commercial aerospace, healthcare, and hard tech have emerged as the market's core pillars. Technological moats, commercial viability, and long-term industrial value have become the industry's shared benchmarks.F...

浏览次数：2

查看详情>>

发布时间: 2026 - 09 - 01

Efung Honor | Efung Capital Wins Dual Awards! Named to [Investors China] 2025-2026 Fund Partners Ran

Recently, Investors China released its prestigious 2025-2026 Fund Partners Ranking. Efung Capital has been honored as one of the Top 50 Best Venture Capital Institutions of 2025-2026, and our CEO, Mr. Zhu Pai, has been recognized among the Top 30 Best Venture Capital Investors of 2025-2026.Over the past year, China's equity investment industry has undergone a profound restructuring and value redefinition. The speculative logic that once profited from hot trends and quick flips is gradually losing its effectiveness. In its place emerges a new competitive landscape rooted in indust...

浏览次数：6

查看详情>>

发布时间: 2026 - 08 - 31

Monthly Health Read | August 2026

In August 2026, competition intensified around the evolution of AI large models toward Agents, the commercialization of embodied intelligence, and breakthroughs in frontier medical technologies such as brain-computer interfaces. The venture capital market exhibited notable characteristics including sustained strong interest in the AI sector, active financing activities in hard tech and healthcare, and robust global VC performance.Against this backdrop, multiple portfolio companies of Efung Capital achieved consecutive breakthroughs in financing rounds and core business expansion.Portfolio...

浏览次数：2

查看详情>>